Key result
The HOPE-HF trial is a randomized crossover study designed to evaluate whether His-bundle pacing improves exercise capacity in 160 heart failure patients, with results expected in 2020.
Why the study?
Does haemodynamically optimized dual chamber His-bundle pacing improve exercise capacity in patients with heart failure, PR prolongation, and narrow QRS or right bundle branch block?
RCT (n=160)
Double-blind
Crossover
Yes
Does haemodynamically optimized dual chamber His-bundle pacing improve exercise capacity in patients with heart failure, PR prolongation, and narrow QRS or right bundle branch block?
The HOPE-HF trial is designed to evaluate whether His-bundle pacing improves exercise capacity and symptoms in heart failure patients with PR prolongation and narrow QRS or RBBB.
AIMS: In patients with heart failure and a pathologically prolonged PR interval, left ventricular (LV) filling can be improved by shortening atrioventricular delay using His-bundle pacing. His-bundle pacing delivers physiological ventricular activation and has been shown to improve acute haemodynamic function in this group of patients. In the HOPE-HF (His Optimized Pacing Evaluated for Heart Failure) trial, we are investigating whether these acute haemodynamic improvements translate into improvements in exercise capacity and heart failure symptoms. METHODS AND RESULTS: This multicentre, double-blind, randomized, crossover study aims to randomize 160 patients with PR prolongation (≥200 ms), LV impairment (EF ≤ 40%), and either narrow QRS (≤140 ms) or right bundle branch block. All patients receive a cardiac device with leads positioned in the right atrium and the His bundle. Eligible patients also receive a defibrillator lead. Those not eligible for implantable cardioverter defibrillator have a backup pacing lead positioned in an LV branch of the coronary sinus. Patients are allocated in random order to 6 months of (i) haemodynamically optimized dual chamber His-bundle pacing and (ii) backup pacing only, using the non-His ventricular lead. The primary endpoint is change in exercise capacity assessed by peak oxygen uptake. Secondary endpoints include change in ejection fraction, quality of life scores, B-type natriuretic peptide, daily patient activity levels, and safety and feasibility assessments of His-bundle pacing. CONCLUSIONS: Hope-HF aims to determine whether correcting PR prolongation in patients with heart failure and narrow QRS or right bundle branch block using haemodynamically optimized dual chamber His-bundle pacing improves exercise capacity and symptoms. We aim to complete recruitment by the end of 2018 and report in 2020.
No takes yet. Share an insight, caveat, or question.
Keene et al. (2018) conducted an RCT in Heart failure (n=160). Haemodynamically optimized dual chamber His-bundle pacing vs. Backup pacing only, using the non-His ventricular lead was evaluated on Change in exercise capacity assessed by peak oxygen uptake. The HOPE-HF trial is a randomized crossover study designed to evaluate whether His-bundle pacing improves exercise capacity in 160 heart failure patients, with results expected in 2020.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: